ENDOMETRIAL NEOPLASMS

This Phase 3 study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy, followed by maintenance durvalumab with or without the targeted drug olaparib, helps people with newly diagnosed advanced or recurrent endometrial cancer. About 805 participants ar…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…

This study tests a new drug called E7386 combined with other cancer drugs in people with advanced solid tumors, including endometrial, liver, and colorectal cancers. The goal is to find the safest and most effective dose and to see if the combination can shrink tumors. About 300 …

This study tests an experimental drug called LY3537982 in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drug is safe and shrinks tumors. About 540 participants with lung, colorectal, endometrial, ovarian, pancreatic, or bile …

This study compares the immunotherapy drug pembrolizumab (Keytruda) to standard chemotherapy (carboplatin + paclitaxel) in 280 women with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR. Participants have not had prior chemotherapy for the…

This early-stage study tests a new drug called BL-M17D1 in 120 adults with advanced solid tumors that have HER2 protein or gene changes. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Participants must have tried at least one standard…

This study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a HER2 marker. The drug is designed to stick to cancer cells and kill them. About 120 adults will receive the drug every two weeks…